Aligos Therapeutics Reports 44% HBV DNA Suppression and 40% HBsAg Reduction at Week 48
ALGS•Phase 1 follow-up of 300 mg pevifoscorvir sodium for 96 weeks showed 44% of HBeAg-positive subjects maintained HBV DNA below 10 IU/mL and 40% with baseline HBsAg ≥3,000 IU/mL fell below 3,000 IU/mL by week 48. Pevifoscorvir plus ASO ALG-170675 showed additive-to-synergistic antiviral effects, supporting functional cure regimens.
1. Phase 1 Follow-Up Results
Phase 1 long-term follow-up of 300 mg pevifoscorvir sodium monotherapy for 96 weeks followed by ≥24 weeks of nucleos(t)ide analog therapy showed 44% of HBeAg-positive subjects maintained HBV DNA below 10 IU/mL throughout the post-treatment period, while 40% of participants with baseline HBsAg ≥3,000 IU/mL achieved HBsAg <3,000 IU/mL by week 48.
2. Antisense Oligonucleotide Combination
Co-administration of pevifoscorvir sodium with antisense oligonucleotide ALG-170675 produced additive-to-synergistic reductions in HBsAg, HBV RNA and other viral markers, suggesting enhanced potential for functional cure regimens in chronic HBV infection.
3. Preclinical Pipeline Advances
In vitro studies of ALG-001075, the active parent moiety of pevifoscorvir sodium, demonstrated durable suppression of HBeAg, HBsAg and intracellular HBV RNAs after treatment withdrawal, while preclinical HDV replication models highlighted novel therapeutic targets within Aligos’ broader liver and viral disease pipeline.
